SCHEMBL5725810

SCHEMBL5725810

CN(C)CCOc1ccc(C(=C(CCO)c2ccc(Cl)cc2)c2ccccc2)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.88
ESR2 Q92731 2/20 0.88
ESRRG P62508 15/20 0.85
HTR6 P50406 2/20 0.74
LMNA P02545 1/20 0.74
ESRRB O95718 3/20 0.70
MAPT P10636 2/20 0.67
MEN1 O00255 1/20 0.67
NPC1 O15118 1/20 0.67
NR1I2 O75469 1/20 0.67
PRKD3 O94806 1/20 0.67
ABCB11 O95342 1/20 0.67
EGFR P00533 1/20 0.67
GBA1 P04062 1/20 0.67
NR3C1 P04150 1/20 0.67
ERBB2 P04626 1/20 0.67
TP53 P04637 1/20 0.67
PRKCG P05129 1/20 0.67
CYP1A2 P05177 1/20 0.67
PRKCB P05771 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5725181 1.00 ESR1 (0.88) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5725184 1.00 ESR1 (0.88) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5738222 1.00 ESR1 (0.88) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5725806 1.00 ESR1 (0.88) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5737012 0.95 ESR1 (0.79) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5725461 0.95 ESR1 (0.79) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL1152584 0.94 ESR1 (1.00) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL1152582 0.94 ESR1 (1.00) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL9099822 0.94 ESR1 (1.00) ESR1ESR2ESRRGHTR6LMNA
SCHEMBL5738741 0.91 ESR1 (0.72) ESR1ESR2ESRRGHTR6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
EP-1235776-B1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORP (FI) 2006-02-08 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 ESR1 2/4885ESR2 1/4885ESRRG 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.